Scholar Rock Holding Corporation (SRRK)
NASDAQ: SRRKHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SRRK stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.87B
- EPS (TTM)
- -$3.23
- Dividend yield
- None
- 52-week range
- 38.69 – 61.76
- Day range
- 47.94 – 52.17
- Volume / Avg
- 2.08M / 1.86M
- Beta
- —
- Shares outstanding
- 122.00M
52-week range
SRRK stock today
Scholar Rock (SRRK) closed at $48.13 on Nov 20, down 4.45% (-$2.24), versus the S&P 500's 3.70% decline. At this level, SRRK sits in the middle of its 52-week range of $38.69 to $61.76: 22.1% below the high, set on Aug 26, 2026 and 24.4% above the low. SRRK is up 9.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 19.7%.
Scholar Rock has posted a net loss over the last twelve months (EPS of -$3.23), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Scholar Rock
Company profileScholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. David L. Hallal
- Headquarters
- Cambridge, MA
- Employees
- 289
- IPO year
- 2018
- Website
- scholarrock.com
Financial highlights
Full financialsIn fiscal 2025, Scholar Rock generated $0 in revenue. Scholar Rock reported a net loss of $377.9 million, compared with a loss of $246.3 million a year earlier. Diluted earnings per share came in at -$3.29.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | — | — | $33.19M | $18.82M |
| Growth | — | — | — | +76.41% | +22.16% |
| Net income | $-377.94M | $-246.29M | $-165.79M | $-134.50M | $-131.80M |
| EPS (diluted) | $-3.29 | $-2.47 | $-1.99 | $-2.26 | $-3.59 |
Analyst forecast
ForecastConsensus (18 analysts)
strong_buy
Avg. price target
$70.06+45.56%
- Strong buy 2
- Buy 14
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.81 vs $-0.87
- Surprise
- +6.90%
SRRK news
All SRRK news- Scholar Rock (SRRK) Q3 2026 Earnings Call TranscriptNasdaq
- What Scholar Rock (SRRK) Said on Its Q3 Earnings CallNasdaq
- Scholar Rock anticipates CHMP opinion in H1 2027 as it monetizes a $205M priority review voucherSeeking Alpha
- BioNTech to buy Scholar Rock Priority Review Voucher for $205MSeeking Alpha
- Scholar Rock Reports Third Quarter 2026 Financial Results and Recent Business HighlightsBusiness Wire
- Scholar Rock Q3 2026 Earnings PreviewSeeking Alpha
- Wednesday 10/28 Insider Buying Report: LRN, SRRKNasdaqLRN, SRRK
- Tuesday’s insider trading: Scholar Rock director buys $12 millionInvesting.com
Scholar Rock peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KODKodiak Sciences Inc | 97.17 | -0.75% | $6.35B | vs SRRK |
| IBRXImmunityBio Inc. | 6.02 | -8.37% | $6.40B | vs SRRK |
| IMVTImmunovant Inc. | 31.77 | -2.31% | $6.57B | vs SRRK |
| TWSTTwist Bioscience Corporation | 103.32 | -7.44% | $7.04B | vs SRRK |
| CGONCG Oncology Inc. | 79.47 | -2.97% | $7.10B | vs SRRK |
| ADPTAdaptive Biotechnologies Corporation | 27.93 | -0.43% | $4.52B | vs SRRK |
| CRSPCRISPR Therapeutics AG | 39.10 | +0.44% | $3.79B | vs SRRK |
| TARSTarsus Pharmaceuticals Inc. | 73.01 | -6.00% | $3.60B | vs SRRK |
Indexes, lists and sector
Scholar Rock stock FAQ
What is Scholar Rock's stock price today?
SRRK last traded at $48.13 as of Nov 20, 4:00 PM EST, down 4.45% on the day. Prices are delayed at least 15 minutes.
Who is Scholar Rock's CEO?
Mr. David L. Hallal is the chief executive officer of Scholar Rock Holding Corporation, which has about 289 employees.
What is the SRRK 52-week high?
The 52-week high for SRRK is $61.76 and the 52-week low is $38.69. The stock is currently 22.1% below its high.